Literature DB >> 27900654

"Slow and steady wins the race": the importance of perseverance in the management of oncogenic osteomalacia.

Maria Manara1, Luigi Sinigaglia2.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27900654     DOI： 10.1007/s12020-016-1187-z

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  9 in total

1.  FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis.

Authors:  Takashi Shimada; Hisashi Hasegawa; Yuji Yamazaki; Takanori Muto; Rieko Hino; Yasuhiro Takeuchi; Toshiro Fujita; Kazuhiko Nakahara; Seiji Fukumoto; Takeyoshi Yamashita
Journal:  J Bone Miner Res       Date:  2003-12-29       Impact factor: 6.741

2.  Clinical utility of systemic venous sampling of FGF23 for identifying tumours responsible for tumour-induced osteomalacia.

Authors:  N Ito; Y Shimizu; H Suzuki; T Saito; T Okamoto; M Hori; M Akahane; S Fukumoto; T Fujita
Journal:  J Intern Med       Date:  2010-10       Impact factor: 8.989

Review 3.  177Lu-DOTATATE PRRT in Recurrent Skull-Base Phosphaturic Mesenchymal Tumor Causing Osteomalacia: A Potential Application of PRRT Beyond Neuroendocrine Tumors.

Authors:  Sandip Basu; Preeti Fargose
Journal:  J Nucl Med Technol       Date:  2016-09-15

Review 4.  Anti-fibroblast growth factor 23 antibody therapy.

Authors:  Seiji Fukumoto
Journal:  Curr Opin Nephrol Hypertens       Date:  2014-07       Impact factor: 2.894

5.  Improving diagnosis of tumor-induced osteomalacia with Gallium-68 DOTATATE PET/CT.

Authors:  Roderick J Clifton-Bligh; Michael S Hofman; Emma Duncan; Ie-Wen Sim; David Darnell; Adele Clarkson; Tricia Wong; John P Walsh; Anthony J Gill; Peter R Ebeling; Rodney J Hicks
Journal:  J Clin Endocrinol Metab       Date:  2013-01-07       Impact factor: 5.958

6.  Tumor localization and biochemical response to cure in tumor-induced osteomalacia.

Authors:  William H Chong; Panagiota Andreopoulou; Clara C Chen; James Reynolds; Lori Guthrie; Marilyn Kelly; Rachel I Gafni; Nisan Bhattacharyya; Alison M Boyce; Diala El-Maouche; Diana Ovejero Crespo; Richard Sherry; Richard Chang; Felasfa M Wodajo; Gad B Kletter; Andrew Dwyer; Michael T Collins
Journal:  J Bone Miner Res       Date:  2013-06       Impact factor: 6.741

7.  Tumor induced osteomalacia: associated with elevated circulating levels of fibroblast growth factor-7 in addition to fibroblast growth factor-23.

Authors:  Shweta Bansal; Khaled Khazim; Rajeev Suri; DeAndra Martin; Sherry Werner; Paolo Fanti
Journal:  Clin Nephrol       Date:  2016-01       Impact factor: 0.975

8.  Selective venous catheterization for the localization of phosphaturic mesenchymal tumors.

Authors:  Panagiota Andreopoulou; Claudia E Dumitrescu; Marilyn H Kelly; Beth A Brillante; Carolee M Cutler Peck; Felasfa M Wodajo; Richard Chang; Michael T Collins
Journal:  J Bone Miner Res       Date:  2011-06       Impact factor: 6.741

9.  Identifying the culprit lesion in tumor induced hypophosphatemia, the solution of a clinical enigma.

Authors:  Mathilde M Bruins Slot-Steenks; Neveen A T Hamdy; Michiel A J van de Sande; Dennis Vriens; Arjen H G Cleven; Natasha M Appelman-Dijkstra
Journal:  Endocrine       Date:  2016-10-05       Impact factor: 3.633
  9 in total
  1 in total

1.  CT and MR imaging features in phosphaturic mesenchymal tumor-mixed connective tissue: A case report.

Authors:  Zhenshan Shi; Yiqiong Deng; Xiumei Li; Yueming Li; Dairong Cao; Vikash Sahadeo Coossa
Journal:  Oncol Lett       Date:  2018-02-05       Impact factor: 2.967
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.